ArticleHereditas2025
In vitro activity of Houttuynia cordata against bacteria isolated from diabetic foot.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMisuse of antibiotics makes it very easy for bacteria to become resistant to drugs. Houttuynia cordata (HC) has antibacterial, antiviral, analgesic, antioxidant, diuretic, hypoglycemic, and immune-enhancing properties.
aimTo study the inhibitory effect of HC on Staphylococcus aureus and Pseudomonas aeruginosa isolated from tissue or pus specimens from patients with diabetic foot ulcers. MATERIALS AND
methodsSeventy-two patients with DFU were randomly divided into three groups and given treatment with methicillin (Met), meropenem (Mer), and HC, respectively. Analysis and identification of clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa using the Orbitrap Exploris™ 480. The drug susceptibility of four isolates to HC was studied by bacteriostatic test. The MIC and MBC of Houttuynia cordata against four isolates were determined using the broth microdilution method. The growth and time-kill curves of the bacteria were studied by bacterial inhibition experiments.The effect of Houttuynia cordata on the viability of H6C7 cells was examined by MTT assay.
resultsHC treatment improved clinical parameters of DFUs patients. The inhibition zone of S08 (MSSA) was 15.45 ± 0.12 mm, which was highly sensitive to Houttuynia cordata. The inhibition zone sizes of R11 (MRSA), P10 (CRPA) and D22 (MDRPA) were 12.64 ± 0.09 mm,13.42 ± 0.11 mm and 11.23 ± 0.08 mm, respectively. All of them were moderately sensitive to Houttuynia cordata. The MIC of S08,R11,P10 and D22 were 31.25,62.5,62.5 and 125 µg/mL, respectively. The MBCS of S08,R11,P10 and D22 were 500,1000,1000 and 1000 µg/mLrespectively.Bacterial growth curves and time-kill curves demonstrated that Houttuynia cordata significantly inhibited the growth of both bacteria. Cytotoxicity assay showed that Houttuynia cordata effectively inhibited bacteria without cytotoxicity to eukaryotic cells.
conclusionHouttuynia cordata exhibits promising antibacterial activity against both Staphylococcus aureus and Pseudomonas aeruginosa, including drug-resistant strains, without cytotoxic effects on eukaryotic cells. These findings support its potential as an alternative therapeutic agent for DFU-associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.